Cholinesterase inhibitors and Alzheimer’s disease: Patient,carer and professional factors influencing the use of drugs for Alzheimer’s disease in the United Kingdom
Restricted accessOtherFirst published online August, 2010
Cholinesterase inhibitors and Alzheimer’s disease: Patient,carer and professional factors influencing the use of drugs for Alzheimer’s disease in the United Kingdom
Between 2001 and 2006 UK guidance recommended that people with mild to moderate Alzheimer’s disease were eligible for treatment with donepezil, rivastigmine and galanatamine on the National Health Service (NHS). However, there was considerable variation in uptake of and access to treatment. This qualitative study aimed to understand which factors influence decisions to initiate, continue and discontinue treatment with the drugs. The views and experiences of 12 older people referred for memory problems or receiving treatment, 11 family carers and 16 health and social care professionals were obtained using a combination of semi-structured interviews and focus groups. Four factors outside UK guidance and prescribing budgets influence decisions to utilize the drug treatments, namely: perceptions of treatment availability and effectiveness; resource capacity; carer perceived benefits; and professional ethics. Unequal access to treatment and ethical concerns remain key issues.
AD2000 Collaborative Group. (2004) Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. The Lancet, 363, 2105-2115.
2.
Alzheimer’s Society (2006). Access to drugs. Retrieved December 19, 2006, from http://www.alzheimers.org.uk/News_and_Campaigns/Campaigning/accesstodrugs.htm .
3.
Bamford, C., & Bruce, E. ( 2002). Success and challenges in using focus groups with older people with dementia. In H. Wilkinson (Ed.), The perspectives of people with dementia: Research methods and motivations (pp. 139-164). London: Jessica Kingsley.
4.
Bamford, C., Eccles, M., Steen, N., & Robinson, L. ( 2007). Can primary care record review facilitate earlier diagnosis of demenita?. Family Practice, 24, 108-116.
5.
Bamford, C., Lamont, S., Eccles, M., Robinson, L., May, C., & Bond, J. ( 2004). Disclosing a diagnosis of dementia: a systematic review . International Journal of Geriatric Psychiatry, 19, 151-169.
6.
Birks, J. ( 2006). Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database of Systematic Reviews 2006, Issue 1. Art No: CD005593. DOI: 10.1002/14651858.CD005593. John Wiley & Sons Ltd.
7.
Birks, J., Grimley Evans, J., Iakovidou, V., & Tsolaki, M. ( 2004). Rivastigmine for Alzheimer’s disease. Cochrane Review. The Cochrane Library, 2004, Issue 1. John Wiley & Sons Ltd.
8.
Birks, J.S., & Harvey, R. ( 2004). Donepezil for dementia due to Alzheimer’s disease . Cochrane Review. The Cochrane Library, 2004 , Issue 1. John Wiley & Sons Ltd.
9.
Clegg, A., Bryant, J., Nicholson, T., McIntyre, L., de Broe, S., & Gerard, K. ( 2002). Clinical and costeffectiveness of donepezil, rivastigmine, and galantamine for Alzheimer’s disease: a systematic review. International Journal of Technology Assessment in Health Care, 18(3), 497-507.
10.
Creswell, J.W. ( 1998). Qualitative inquiry and research design: Choosing among five traditions. London: SAGE Publication .
11.
Department of Health (2001) Research Governance Framework for Health and Social Care. London: Department of Health.
12.
Folstein, M.F., Folstein, S.E., & McHugh, P.R. (1975). Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189-198.
13.
Gray, R. ( 2001). Improvements in functional ability with galantamine in Alzheimer’s have not yet been established [Rapid response letter]. British Medical Journal, 321(7274), 1445.
14.
Hart, J.T. ( 1971). The inverse care law. The Lancet, 1(7696), 405-412.
15.
Horton, R. ( 2007). NICE vindicated in UK’s high court. The Lancet, 370(9587), 547-548.
16.
Jones, R.W. ( 2004). Dementia, postcode prescribing and NICE. Age and Ageing, 33(4), 331-332.
17.
Jones, R.W. ( 2007). Commentary on ‘Health economics and the value of therapy in Alzheimer’s disease’. Drug treatment of Alzheimer’s disease: The United Kingdom experience - National Institute for Health and Clinical Excellence guidance and guidelines for dementia. Alzheimer’s & Dementia, 3(3), 180-185.
18.
Lovestone, S., & Murray, D. ( 2001). Acetylcholinesterase treatment - modelling potential demand and auditing practice. International Journal of Geriatric Psychiatry, 16, 1136-1142.
19.
Mace, S., & Taylor, D. ( 2002). Adherence to NICE guidance for the use of anticholinesterases for Alzheimer’s disease. Pharmaceutical Journal, 269, 680-681.
20.
Masters, C.L., & Beyreuther, K. (1998). Science, medicine and the future: Alzheimer’s disease. British Medical Journal , 316, 446-448.
21.
Matthews, F.E., McKeith, I., Bond, J., & Brayne, C. ( 2006). Reaching the population with dementia drugs: what are the challenges?. International Journal of Geriatric Psychiatry , 22(7), 627-631.
22.
Mazur, D.J. ( 2003). The new medical conversation: Media, patients, doctors, and the ethics of scientific communication. Oxford: Rowman & Littlefield Publishers Inc.
23.
McNamee, P., Bond, J., & Buck, D. & the Resource Implications Study of the Medical Research Council Cognitive Function and Ageing Study (2001). Costs of dementia in England and Wales in the 21st century. British Journal of Psychiatry, 179, 261-266.
24.
Melzer, D. ( 1998). New drug treatment for Alzheimer’s disease: lessons for healthcare policy. British Medical Journal, 316, 762-764.
25.
Moise, P., Schwarzinger, M., & Um, M.-Y.Dementia Experts’ Group (2004) Dementia care in 9 OECD Countries. Paris: OECD.
26.
National Institute for Clinical Excellence ( 2001) Guidance on the use of Donepezil, Rivastigmine and Galantamine for the treatment of Alzheimer’s disease. London : National Institute for Clinical Excellence.
27.
National Institute for Clinical Excellence. ( 2005). Appraisal Consultation Document: Donepezil, rivastigmine, galantamine and memantine for the treatment of Alzheimer’s disease. London: National Institute for Clinical Excellence . Retrieved 1 April, 2005 from http://www.nice.org.uk/page.aspx?o=245912.
28.
National Institute for Health and Clinical Excellence. ( 2006). Appraisal Consultation Document: Donepezil, rivastigmine, galantamine and memantine for the treatment of Alzheimer’s disease. London: National Institute for Health and Clinical Excellence. Retrieved 23 January, 2006 from http://www.nice.org.uk/page.aspx?o=245912.
29.
National Institute for Health and Clinical Excellence. ( 2007). Outcome of judicial review for NICE guidance on drugs for Alzheimer’s Disease. london: National Institute for Health and Clinical Excellence. Retrieved 23 April, 2008 from http://www.nice.org.uk/newsevents/infocus/infocusarchive/OutcomeofJR.jsp.
30.
Olin, J., & Schneider, L. ( 2004). Galantamine for dementia due to Alzheimer’s disease. Cochrane Review. The Cochrane Library 2004, Issue 1. John Wiley & Sons Ltd.
31.
Ritchie, J., & Spencer, L. ( 1994). Qualitative data analysis for applied policy research . In A. Bryman, & R. G. Burgess (Eds.), Analyzing qualitative data (pp. 173-194). London & New York: Routledge.
32.
Schneider, L.S. ( 2004). AD2000: donepezil in Alzheimer’s disease. The Lancet, 363, 2100-2101.
33.
Schwartz, S., & Griffin, T. ( 1986). Medical thinking: The psychology of medical judgment and decision making. New York: Springer-Verlag.
34.
Sheldon, T.A., Cullum, N., Dawson, D., Lankshear, A., Lowson, K., & Watt, I. ( 2004). What’s the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients’ notes, and interviews. BMJ, 329(7473), 999-1003.
35.
Strauss, A., & Corbin, J. ( 1998). Basics of qualitative research: Techniques and procedures for developing grounded theory (2nd ed.). Thousand Oaks: SAGE Publications.
